Stories from Balerna

26.03.2020 – 15:41

APR
FDA Grants Orphan Drug Designation to APR-OD031 for the Treatment of Phenylketonuria (PKU)

Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research s.a. ("APR"), the Swiss pharma company leveraging drug delivery technologies to develop innovative products for niche and rare diseases, today announced that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for the Company's drug candidate APR-OD031 for the treatment ...

more
04.12.2019 – 12:22

APR Applied Pharma Research s.a.
FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa

Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research sa ("APR"), the Swiss pharma company focused in niche and rare therapeutic areas, announces that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for its investigational drug code-named APR-TD011 for treatment of ...

more
11.06.2019 – 12:00

APR Applied Pharma Research s.a.
29th EWMA Conference: Latest Clinical Data on Nexodyn® AOS Demonstrating Higher Healing Performance in Chronic Leg Ulcers Presented by Applied Pharma Research

Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research sa (APR) presented at the recent 29th conference of the European Wound Management Association (EWMA) in Göteborg, the results of a clinical study confirming Nexodyn® AcidOxidizing Solution (AOS) to promote the restart of the healing process in ...

more

1